Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Nurix Therapeutics's NX-1607?
NX-1607 is a small molecule commercialized by Nurix Therapeutics, with a leading Phase I program in Solid Tumor. According to...
Data Insights
Risk adjusted net present value: What is the current valuation of Nurix Therapeutics's NX-1607?
NX-1607 is a small molecule commercialized by Nurix Therapeutics, with a leading Phase I program in Metastatic Transitional (Urothelial) Tract...